Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00055445 · ClinicalTrials.gov registry record · Phase 1
IdB 1016 Treatment for Hepatitis C Disease
A Phase 1 study of Hepatitis C, Chronic, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- Completed
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT00055445 is a Phase 1 study of Hepatitis C, Chronic that has completed, run by National Center for Complementary and Integrative Health (NCCIH). The registered enrollment target is 45 participants, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00055445, a Phase 1 study of Hepatitis C, Chronic, has completed, sponsored by National Center for Complementary and Integrative Health (NCCIH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will measure the safety and tolerability of three different doses of IdB 1016 in patients with hepatitis C disease who have not responded to or are poor candidates for interferon-based therapies. NOTE: THE STUDY WILL ONLY RECRUIT STUDY PARTICIPANTS AT UNIVERSITY OF WASHINGTON MEDICAL CENTER IN SEATTLE
Conditions Studied
Interventions
- DRUG IdB 1016
Study Locations (1)
Washington
- University of Washington Medical Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00055445
The ClinicalTrials.gov registry entry for NCT00055445 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 374-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (88% lower). The listed sponsor is National Center for Complementary and Integrative Health (NCCIH), which has 203 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 1 intervention - of which IdB 1016 is the first listed.
NCT00055445 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.
Frequently Asked Questions
What is clinical trial NCT00055445 about?
NCT00055445 is a clinical study titled "IdB 1016 Treatment for Hepatitis C Disease". This study will measure the safety and tolerability of three different doses of IdB 1016 in patients with hepatitis C disease who have not responded to or are poor candidates for interferon-based therapies. NOTE: THE STUDY WILL ONLY RECRUIT STUDY PARTICIPANTS AT UNIVERSITY OF WASHINGTON MEDICAL CEN...
What is the current status of trial NCT00055445?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2003-11. Estimated completion is 2006-04.
What conditions does trial NCT00055445 study?
This clinical trial studies the following conditions: Hepatitis C, Chronic.
What interventions are being tested in trial NCT00055445?
The interventions under investigation include: IdB 1016 (DRUG).
Who is sponsoring clinical trial NCT00055445?
This trial is sponsored by National Center for Complementary and Integrative Health (NCCIH), which has 203 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00055445 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hepatitis C, Chronic
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
COMPLETED · Phase 1
-
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
COMPLETED · Phase 1
-
Study of PEG-rIL-29 (or PEG-IFN Lambda) in Subjects With Chronic Hepatitis C Virus Infection
COMPLETED · Phase 1
-
Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy
RECRUITING · Phase 4
-
People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents
ACTIVE NOT RECRUITING · Phase 4
-
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.